Melanoma
1 – 10 of 93
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Systemic and local decorin levels mirror the clinical course of pancreatic cancer
- Contribution to journal › Article
-
Mark
Modeling anti-tumor immune responses using patient-derived melanoma organoids
- Contribution to journal › Article
-
Mark
Spatial and temporal dynamics of cancer-associated fibroblast niches in breast cancer
- Contribution to journal › Article
-
Mark
SWE-NEO : Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial
- Contribution to journal › Letter
-
Mark
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis
- Contribution to journal › Article
-
Mark
Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma : A retrospective cohort study
- Contribution to journal › Article
-
Mark
The FOCU.SE trial : a nationwide Swedish drug repurposing protocol and research framework
- Contribution to journal › Letter
-
Mark
The Effects of Sun Exposure and Pigmentation Phenotype on Prognosis in Metastatic Melanoma
- Contribution to journal › Article
- 2025
-
Mark
An Activin Receptor-Like Kinase 1-governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases
- Contribution to journal › Article
-
Mark
Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma
- Contribution to journal › Article
